Delivery Order SPE2DB24D1205-SPE2DB25FCZEF
- Not listed
- The Defense Logistics Agency awarded a $1,165.05 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENVARSUS XR 1 mg tablets (30-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. This non-competitive set-aside delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, holds a substantial...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $1,711.95 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of ENVARSUS XR 4 MG TABLET 100S. The contract has a completion date of July 1, 2025 and is not a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00,...
- This is a $1,615.33 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of ENVARSUS XR 4 MG TABLET 100S. The contract has an ultimate completion date of September 19, 2024. AmerisourceBergen, a major pharmaceutical distributor, is providing these prescription medications to support military treatment facilities and other federal healthcare providers. This delivery order is part of a larger Indefinite Delivery Contract...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,711.95 firm-fixed-price contract is for the delivery of ENVARSUS XR 4 MG TABLET 100S, a pharmaceutical product. The contract has an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,711.95 contract is for the supply of ENVARSUS XR 4 MG TABLET 100S, a medication. The contract has an ultimate completion date of July 14, 2025. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $1,216.11 contract is for the provision of ENVARSUS XR 1 MG TABLET 100S, a pharmaceutical product, with a period of performance through April 22, 2024. This delivery order is a task order under an indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of up to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract, valued at $11,313.46, is for the delivery of ENVARSUS XR 4 MG TABLET 100S to support military treatment programs and facilities. Amerisourcebergen Drug Corp, the prime contractor, serves as the primary supplier of pharmaceutical products...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for $1,615.33 to supply ENVARSUS XR 4 MG TABLET 100S. This order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Amerisourcebergen, valued up to $999,999,999.00 through December 31, 2025. Under this IDC, Amerisourcebergen provides a comprehensive range of pharmaceutical products and...
- The Defense Logistics Agency Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of ENVARSUS XR 1 MG TABLET 100S. The contract has a completion date of March 8, 2024 and a potential value of $1,216.11. This delivery order contract is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, a firm fixed price delivery order contract valued at $1,615.33 to provide ENVARSUS XR 4 MG TABLET 100S. This award is under Amerisourcebergen's existing indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for Amerisourcebergen to deliver pharmaceuticals and medical supplies to DLA Troop...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZEFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for ENVARSUS XR 4 MG tablets (100-count units), with an ultimate completion date of August 25, 2025. This is a firm fixed price, non-set-aside delivery order issued under a competitively awarded contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime vendor agreement enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The delivery order award reflects the company's ongoing capability to fulfill federal medical supply needs through open competition and competitive pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/4/25 |